ReBeL study: a randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients ≥ 18 years with relapsed follicular lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Bendamustine (Primary) ; Lenalidomide; Rituximab
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms HOVON110FL-GLSG-NCRI; ReBeL
- 18 Aug 2015 Planned End Date changed from 1 Oct 2025 to 1 Oct 2015, as reported by United Kingdom Clinical Research Network.
- 18 Jul 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2025 as reported by UK Clinical Trials Register record.
- 13 Jul 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2011-000097-56).